10x Genomics (TXG)
The United States Court of Appeals for the Federal Circuit Affirms That 10x Genomics Willfully Infringed Bio-Rad U.S. Patent and Upholds Lower Court’s Award of Damages
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago. The Appeals Court upheld the lower Court’s finding on monetary damages amounting to $23.9 million at the time of the trial, No
Fund manager Tom O'Halloran quadrupled investors' money in 9 years by betting on super high-growth companies. He explained his approach, and why new technologies could make the next decade for markets even better than the 2010s.
Thomas O'Halloran manages the Lord Abbett Growth Leaders Fund , which has more than quadrupled investors' money in nine years by investing in high-growth tech, consumer, and healthcare stocks. He's even more optimistic about the coming decade, reasoning that the combination of the "technology revolution" and low interest rates should keep a secular bull market going through 2030. He also says there's little reason to worry about the market dominance of Big Tech because companies like Microsoft and Amazon are innovating in ways that help other companies succeed. Click here to sign up for our weekly newsletter Investing Insider . Visit Business Insider's homepage for more stories . A lot of experts go back and forth between praising Big Tech and worrying that it is dangerously dominant — but Thomas O'Halloran is consistent in thinking the companies deserve their success. "These companies are the greatest companies the planet has ever seen," he said of Apple , Microsoft , Amazon , Alphabet , and Facebook . "I don't worry about it at all, the concentration.
10x Genomics - Growing One Cell At A Time (NASDAQ:TXG)
10x Genomics is growing fast and likely to become a successful life science tools company. 10x Genomics is leading the cell revolution and offering investors an opportunity to invest in the market at an early stage.
An investment chief who doubled 3 of her firm's ETFs within 3 years told us the most overlooked technological innovation on her radar — and shared the 3 stocks she's been snapping up since the pandemic started
Ark Invest's Genomic Revolution ETF is crushing the market this year, and investment chief and portfolio manager Cathie Wood says investors still haven't woken up to the potential of the technology. The ETF has rocketed more than 60% this year and more than doubled its value in the last three years. Wood also told Business Insider about three stocks she bet on during the market downturn this year. Click here to sign up for our weekly newsletter Investing Insider . Visit Business Insider's homepage for more stories . If Cathie Wood wanted to gloat and say her investing philosophy has been vindicated, she could probably get away with it. She founded Ark Invest in 2014 to bet on companies and technologies that had the potential to change the world, and argues that innovation itself should be a piece of any investor's portfolio, similar to fixed income or emerging markets. To get the word out, Wood decided that her firm would launch actively-traded ETFs and give away its research for free.
Torex Gold Resources reports 1Q adjusted profit
A roundup of all the mining news in the precious metals sector with a variety of company news, mining sector analysis, newsletter writer insights and executive interviews.
Torex Gold Updates Resource Estimate for Media Luna
Torex Gold Resources has released an updated resource estimate for the Media Luna project located in Mexico. The post Torex Gold Updates Resource Estimate for Media Luna appeared first on Investing News Network .
The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Crispr Therapeutics AG (NASDAQ: CRSP ) DexCom, Inc. (NASDAQ: DXCM Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) )(announced a partnership with Novo Nordisk A/S (NYSE: NVO ) for developing RNAi therapies) Frequency Therapeutics Inc (NASDAQ: FREQ )(reacted to its third-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Karuna Therapeutics Inc (NASDAQ: KRTX )( announced positive results for its mid-stage schizophrenia drug) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO )(announced full results of its ORION-9 Phase 3 study of inclisiran at the American Heart Association 2019 annual meeting) Medtronic PLC (NYSE: MDT ) Neurocrine Biosciences, Inc.
The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
Xander sets up $250 mn industrial real estate platform for India
MUMBAI: The global investment firm the Xander Group’s private equity real estate arm Xander Investment Management (XIM) has set up an industrial real estate platform for India. XIM Singapore will act as the investment advisor to the platform that will invest $250 million or over Rs 1,780 crore in high quality assets over the next 12 months.The venture will acquire assets in the high growth logistics and e-commerce sector along key industrial corridors across leading Indian cities, Xander said in a release.Sponsored by the Xander Group, the platform has raised capital from leading European institutional investors that have previously been limited partners in XIM sponsored opportunity funds.“We have been investing opportunistically in the industrial/ logistics sector since 2007. With the economy poised for retail, manufacturing and consumption growth, it is the opportune time for us to create a platform with like-minded investors that will execute a longer term, targeted program,” said Rohan Sikri, Senior Partner, TXG and Managing Director, XIM.The platform has been seeded with a portfolio of two million sq ft incubated by Xander.
Follow Us